Abstract

Stability of Venlafaxine Immediate-Release Suspensions

Author(s): Donnelly Ronald F, Wong Keith, Goddard Rob, Johanson Christel

Issue: Jan/Feb 2011 - Volume 15, Number 1

Page(s): 81-84

Download in electronic PDF format for $75
  • Stability of Venlafaxine Immediate-Release Suspensions Page 1
  • Stability of Venlafaxine Immediate-Release Suspensions Page 2
  • Stability of Venlafaxine Immediate-Release Suspensions Page 3
  • Stability of Venlafaxine Immediate-Release Suspensions Page 4

Note: Electronic version includes errata or revisions.

Abstract

Venlafaxine is a novel antidepressant that works by inhibiting the reuptake of serotonin and norepinephrine. The objectives of this study were to reformulate a venlafaxine extended-release suspension into an immediate-release preparation and then determine the physical and chemical stability of the new venlafaxine formulation. Suspensions of venlafaxine (75 mg/5mL) were prepared from extended-release microspheres that had been reduced to powder and then dispersed in either OraPlus/OraSweet (50:50) or simple syrup. Triplicate samples of the suspensions were collected from amber plastic bottles stored at either 5ºC or 23ºC on days 0, 7, 14, 21, and 28, and assayed. Physical stability was based on color and pH changes. A validated high-performance liquid chromatography assay method was used to determine the chemical stability of the active ingredient. This study found that venlafaxine immediate-release suspensions, prepared in either OraPlus/OraSweet or simple syrup, are physically and chemically stable for 28 days when stored in amber plastic bottles at either 5ºC or 23ºC.

Related Keywords

  • venlafaxine
  • antidepressant
  • immediate release suspension
  • stability
  • excipients

Related Categories

  • MENTAL HEALTH
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2011
Pg. 81-84
Stability of Venlafaxine Immediate-Release Suspensions
Author(s): Donnelly Ronald F, Wong Keith, Goddard Rob, Johanson Christel
Mar/Apr 2011
Pg. 175
Erratum: Stability of Venlafaxine Immediate-Release Suspensions
Author(s): Allen Loyd V Jr
May/Jun 2009
Pg. 259-261
Formulation Optimization Study for an Immediate-Release Tablet
Author(s): Kyriacos Soula, Dimassi Hani
Sep/Oct 2021
Pg. 364-371
Filling the Gaps on the Institute for Safe Medication Practices (ISMP) Do Not Crush List for Immediate-release Products
Author(s): Uttaro Elizabeth, Zhao Fang, Schweighardt Anne
Sep/Oct 2017
Pg. 418-425
Kinetic Analysis of Drug Release from Compounded Slow-release Capsules of Liothyronine Sodium (T3)
Author(s): Bakhteyar Hamid, Cassone Clayton, Kohan Hamed Gilzad, Sani Shabnam N
May/Jun 2020
Pg. 233
Venlafaxine 15 mg/mL in Ora-Plus:Ora-Sweet (1:1) Suspension
Author(s): Allen Loyd V Jr
Sep/Oct 2003
Pg. 389-393
Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Author(s): Alexander Kenneth S, Thyangarajapuram N
Jan/Feb 2013
Pg. 10-22
Compounding Slow-release Capsules: A Comprehensive Review and an Excel Spreadsheet for Faster Calculation of Excipients
Author(s): Zur Eyal
Sep/Oct 2001
Pg. 401-405
Release of Morphine Sulfate from Compounded Slow-Release Capsules: The Effect of Formulation on Release
Author(s): Bogner Robin H, Szwejkowski Jessica, Houston Alana
Mar/Apr 1997
Pg. 128-131
Stability of Allopurinol Suspension Compounded from Tablets
Author(s): Alexander Kenneth S, Davar Nipun, Parker Gordon A
Jan/Feb 2020
Pg. 63
Venlafaxine 15 mg/mL in Syrup
Author(s): Allen Loyd V Jr
Sep/Oct 2023
Pg. 431-439
The Influence of Polymers, Surfactants, and Other Excipients on Naproxen Sodium Release from Matrices Prepared and the Effect of These Additives on the Swelling Rate of the Tablet
Author(s): Alhmoud Hassan, Akkam Yazan, Omari Derar, Alghananim Alaa, Melhem Mohammad Bani
Jan/Feb 2022
Pg. 65-71
Physical Stability and Release Profile of Compounded Gabapentin Containing Pluronic Lecithin Organogel for Neuropathic Pain Management
Author(s): Hong Eun Ji, Sumanasekera Wasana, Le Uyen Minh
Sep/Oct 2013
Pg. 424-431
In Vitro Evaluation of Extemporaneously Compounded Immediate-release Capsules with Premixed Excipients, Based on the Biopharmaceutics Classification System (BCS) of the Drugs
Author(s): Pinheiro Vanessa A, Danopoulos Panagiota, Demirdjian Lara, Nogueira Rodrigo J L, Dubois Fanny
Jul/Aug 2017
Pg. 322-329
Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
Sep/Oct 2021
Pg. 431-439
Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Author(s): Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Jul/Aug 2022
Pg. 283-291
Evaluation of the Physical-chemical Characteristics and Biopharmaceutical Performance of Dilu-Cap: A Complete Line of Excipients for Hard-shell Capsules
Author(s): de Oliveira Ferreira Anderson, Polonini Hudson
Mar/Apr 2017
Pg. 160-163
Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Author(s): Kabiche Djamila, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
May/Jun 2003
Pg. 233-239
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Author(s): Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
Jan/Feb 2023
Pg. 72-77
Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base
Author(s): Spennacchio Antonio, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio